Ariad halts clinical trial of Iclusig due to safety concerns

10/20/2013 | Genetic Engineering & Biotechnology News

Ariad Pharmaceuticals has announced the discontinuation of the Phase 3 trial of its chronic myeloid leukemia drug, Iclusig, due to reports of increased blood clots in patients. Ariad and the FDA mutually agreed that the trial should be terminated, a decision which came a week after the agency placed the drug on partial clinical hold. The company said that the decision was made in the interest of patient safety based on recent assessment of data in the clinical trial.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park